Browse studies

Find your next paid study

8 recruiting studies matching your filters

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patie…

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06422806

Phase 1

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usu…

Advanced Dedifferentiated LiposarcomaAdvanced LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06498648

Phase 1

A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for High-Risk Adipocytic Retroperitoneal Sarcomas

This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation therapy before surgery in treating patient…

Retroperitoneal SarcomaLiposarcomaDedifferentiated Liposarcoma

Estimated

~$10 – $6,250

University of WashingtonNCT06025747

Phase 1

A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma

The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, re…

Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcoma+6 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06843967

Phase 1

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sar…

Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05711615

Phase 1

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 …

Solid TumorSarcomaLeiomyosarcoma+1 more

Estimated

~$10 – $8,750

STORM Therapeutics LTDNCT06975293

Phase 1

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free surviva…

Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+39 more

Phase 1

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this …

Solid TumoursSarcomaHNSCC+12 more

Estimated

~$10 – $7,500

EpkinNCT06789172